Report Store Get Proposal

Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

Home Blog Immunological and autoimmune disorders

Immunological and Autoimmune Disorders

Pharma-news-for-prolong-shorla-novartis

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Prolong’s PP-007 Fast-Tracked for Stroke; FDA Expands JYLAMVO Pediatric Approval; Corcept’s Cushing’s Drug Shows Positive Phase III Results; ESSA Halts Phase II Study of Masofaniten for Prostate Cancer; SCEMBLIX Approved for Leukemia

Prolong Pharmaceuticals Secures FDA Fast Track for PP-007 in Stroke Therapy Prolong Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company, announced that its investigational therapy, PP-007 (PEGylated carboxyhemoglobin, bovine), has been granted Fast Track designation by the FDA for the treatment of acute ischemic stroke. This designation highlights the FDA’s recognition of PP-007’s potential to address critical needs in stroke treatment. The therapy is currently under evaluation in the ongoing HEMERA-1 clinical trial in the United States, focused on assessing its safety and efficacy. With over 700,000 ischemic strokes occurring each year in the U.S. ...

Explore More...

potential-of-exosomes

Exosomes: Tiny Messengers with Big Potential in Medical Science

7-key-companies-developing-trispecific-antibodies

7 Companies at the Forefront of Trispecific Antibody Development

Which Key Player Holds the Potential to Corner the Rheumatoid Arthritis Therapeutics Market

Which Key Player Holds the Potential to Corner the Rheumatoid Arthritis Therapeutics Market?

Fierce Competition Lies Ahead for Pipeline Therapies in the Rheumatoid Arthritis Market

Fierce Competition Lies Ahead for Pipeline Therapies in the Rheumatoid Arthritis Market

Understanding Rheumatoid Arthritis Epidemiology Trends and Market Insights

Understanding Rheumatoid Arthritis: Epidemiology Trends and Market Insights

The Present Rheumatoid Arthritis Treatment Market Offers a Mix-and-Match Approach

The Present Rheumatoid Arthritis Treatment Market Offers a Mix-and-Match Approach

6-promising-bispecific-antibodies-beyond-oncology

6 Upcoming Bispecific Antibodies Beyond Oncology

Pharma-news-for-astrazeneca-sanofi-UCB

Zevra’s MIPLYFFA Niemann-Pick Disease Approval; FASENRA Approved for Eosinophilic Granulomatosis; Sanofi’s SARCLISA Gets Multiple Myeloma Approval; RYBREVANT Combo Gets FDA Nod for EGFR Lung Cancer; UCB’s BIMZELX Receives Multiple Approval from the FDA

Pharma-news-for-gilead sciences-syndax-astrazeneca

Gilead’s Livdelzi FDA Approval for Primary Biliary Cholangitis; Incyte and Syndax’s Niktimvo Approved for Graft-Versus-Host Disease; FDA Lifts Hold on BioNTech and MediLink’s ADC Cancer Trial; FDA Approves IMFINZI for Resectable Lung Cancer; Yutrepia Receives Tentative Approval for PAH and PH-ILD

pharma-news-for-ascendis pharma-novartis-servier

FDA Approves Ascendis Pharma’s YORVIPATH; ARS Pharma Gets FDA Green Light for First Nasal Spray; FDA Rejects Lykos’ MDMA-Assisted PTSD Therapy; Novartis’ FABHALTA Receives FDA Accelerated Approval; Servier Snags FDA Approval for Voranigo

fcrn-inhibitors-in-20-indications

FcRn Inhibitors Being The Fastest Growing Class, Plans To Get Explored In 20+ Indications

pharma-news-for-eisai-merck-verona-astrazeneca

Eisai Announces Solo Development of Farletuzumab Ecteribulin (FZEC); Johnson & Johnson’s Nipocalimab Phase III Trial; Merck’s WINREVAIR EU CHMP Recommendation; Verona Pharma’s Ohtuvayre FDA Approval; AstraZeneca’s Lynparza and Imfinzi EU Approval

fcrn-inhibitors-for-autoimmune-disorders

FcRn Inhibitors for Autoimmune Disorders: A Promising Therapeutic Approach

Pharma News for BeiGene, GSK, Sandoz, Travere

BeiGene’s BRUKINSA Gets FDA Accelerated Approval; GSK’s Positive Results in DREAMM-8 Phase III; Sandoz’s Denosumab Biosimilars FDA Approved; Terns Pharma’s TERN-701 Receives Orphan Drug Designation; Wegovy® Approved in US for Overweight Cardiovascular Risk; Travere Therapeutics Submits sNDA for FILSPARI IgAN Full Approval

AAAAI Annual Meeting Highlights

Major Highlights and Insights from the AAAAI Annual Meeting, 2024

Pharma News for Bayer, AstraZeneca, AbbVie, A2 Bio

Bayer’s New Cardiology Drug Acoramidis; Two Datopotamab Deruxtecan Applications Validated in the EU; AbbVie and OSE Immunotherapeutics Announce Announces Partnership; vTv Therapeutics Makes Major Move With Cadisegliatin; A2 Bio Scores FDA Orphan Drug Designation for its Therapy, A2B530; FDA Fast Track Designation for AlloNK® in Lupus Nephritis

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Daily

Weekly

Monthly